Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Trial Profile

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs HIV vaccine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms EVA TAT
  • Sponsors Biosantech
  • Most Recent Events

    • 15 Mar 2016 According to Biosantech media release, based on the results of this trial, the company will put forward request for a phase III trial (see CTP 700269274) of its anti-HIV vaccine for an extensive evaluation during 2016 and intends to request a MAA for its anti-HIV vaccine in second half of 2018.
    • 15 Mar 2016 According to Biosantech media release, the detailed results of this trial have been published in the scientific journal Retrovirology.
    • 15 Mar 2016 Results published in the Biosantech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top